Advanced/Metastatic Solid Tumors research hub
16 indexed studies · 10 currently recruiting
- recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · China - active not recruitingPHASE1, PHASE2
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
This study investigates new ways to treat advanced bladder cancer (urothelial cancer) that has spread or is locally advanced. It combines a drug called erdafitinib, which targets specific cancer changes, with cetrelimab and/or chemotherapy. The aim is to find safe doses and see how well these treatments work.
United States · Belarus · Belgium - recruitingPHASE1, PHASE2
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This study looks at new treatments for bladder cancer (and related areas) that has spread or is advanced, especially when previous treatments haven't worked well. It tests different medicines to see if they can help patients whose cancer hasn't responded to standard immune-boosting drugs.
United States · Australia · Canada - active not recruitingPHASE3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study looks at new treatments for bladder and related cancers that have spread. We want to see if combining two drugs, disitamab vedotin and pembrolizumab, works better than standard chemotherapy. It also checks for side effects.
United States · Argentina · Australia - recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This study is testing a new drug, AVA6000, for people with advanced solid tumours like breast, ovarian, or salivary gland cancer. It aims to find a safe dose and see how well it works when standard treatments may no longer be effective.
United States · United Kingdom - recruiting
A Study of Ward Admissions for Haematuria
This study looks at how hospitals in the UK and other countries manage patients who come in with blood in their pee (haematuria). The aim is to find the best ways to treat this condition and improve care for everyone.
United Kingdom - active not recruitingPHASE3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This study looks at a new treatment called cretostimogene grenadenorepvec for a type of bladder cancer that hasn't spread into the muscle. It compares giving this treatment after surgery to just monitoring patients. The aim is to see if the new treatment can stop the cancer from coming back.
United States · Canada - recruiting
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
This study looks at a new urine test for bladder cancer. It aims to see if this simple test can help reduce the need for uncomfortable bladder examinations (cystoscopies) in people who have blood in their urine or other signs that might suggest cancer.
United States · Canada · Finland - recruitingNA
Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
This study looks for early signs of bladder and kidney cancers in people with Lynch syndrome. We're testing a new urine test to see if it can find these cancers sooner than current methods, helping people get treatment earlier.
Canada · Finland - recruiting
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
This study looks at combining special cancer drugs (PD-1/PD-L1 inhibitors) with radiation. It aims to see how well this works for various cancers and if we can find new ways to predict who will benefit most from this treatment.
Germany - recruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
United States · Australia · Canada - recruitingPHASE2
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
This study looks at combining two treatments — immunotherapy and a special type of radiotherapy called carbon ion therapy — for certain cancers that haven't worsened with current immunotherapy. It aims to see if this combination is safe and effective.
Germany · Italy - recruitingPHASE2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study looks at new treatments for a type of bladder cancer called urothelial cancer. Researchers want to see if drugs called disitamab vedotin and pembrolizumab can help people whose cancer has spread or is hard to remove, and to check for side effects.
United States · Argentina · Australia - active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Argentina · Austria · Belgium - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
France